Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
IPO Year: 2011
Exchange: NASDAQ
Website: fluidigm.com
Piper Sandler reiterated coverage of Fluidigm with a rating of and set a new price target of $8.00 from $15.00 previously
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
424B3 - STANDARD BIOTOOLS INC. (0001162194) (Filer)
EFFECT - STANDARD BIOTOOLS INC. (0001162194) (Filer)
S-3 - STANDARD BIOTOOLS INC. (0001162194) (Filer)
10-Q - STANDARD BIOTOOLS INC. (0001162194) (Filer)
DEF 14A - STANDARD BIOTOOLS INC. (0001162194) (Filer)
DEFA14A - STANDARD BIOTOOLS INC. (0001162194) (Filer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (NASDAQ:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm, the Company's new President, Chief Executive Officer and a member of the Company's Board of Directors, and Hanjoon (Alex) Kim, the Company's new Chief Operating Officer, and a new employee, Ardalan (Alex) Arfaei, the Company's new Senior Vice President, Corporate Development. In accordance with Nasdaq Listing Rule 5635(c)(4), Standard BioTools' Compensation Committee of its Board of Directors, which is composed entirely
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Dr. Carlos V. Paya, chairman of Fluidigm, said, "On behalf of the Board of Directors, I would like to thank our stockholders for their support of this investment, which is expected to fuel a realization of identified growth and cost opportunities within the Company's two major platforms, mass cytometry and microfluidics, and pave the way
Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm's current largest holder of common stock, under which Caligan has agreed to vote "FOR" all Fluidigm proposals related to the
Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting Parties to Terminate the Purchase Agreements if Stockholder Approval is Not Received on April 1 SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into an agreement with Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking") modifying the provision of the proposed strategic capital infusion transaction that permitted Fluidigm to adjourn the Special Meeting of Stockholders ("Special Meeting") to April 1, 2022, instead of the allowed aggregate of 20 business days. Importantly, the parties will terminate the p
SOUTH SAN FRANCISCO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it convened and then adjourned, without conducting any other business, the Company's Special Meeting of Stockholders (the "Special Meeting") to provide stockholders additional time to vote on the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). The Special Meeting was adjourned until 9:00 a.m., Pacific time, on April 1, 2022. All stockholders of record at the close of business on February 18, 2022, remain entitled to vote their shares at the Special Meeting. The S
SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today urged Fluidigm stockholders to vote "FOR" ALL proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking") at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting"). The Special Meeting is scheduled for March 25, 2022. MAXIMIZE THE VALUE OF YOUR INVESTMENT BY VOTING "FOR" ALL PROPOSALS! This transaction is the culmination of the Fluidigm Board's comprehensive review of a wide range of options to maximize stockholder value. The investment by
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. ("Glass Lewis") have recommended that Fluidigm stockholders vote "FOR" ALL proposals related to the previously announced strategic capital infusion from leading life sciences and biotechnology-focused investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking") at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 25, 2022. In its March 8, 2022 report, ISS stated1, "A vote FOR the proposal is war
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December 31, 2021. "We are pleased with our performance in the fourth quarter as we made significant progress mitigating ongoing supply chain issues and getting as many products as possible into the hands of our customers," said Chris Linthwaite, President and CEO. "Our team addressed several supply chain bottlenecks and worked through a substantial backlog of unfilled orders, particularly in the APAC reg
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for development of targeted stem cell therapies and research applications utilizing two Fluidigm® mass cytometry and tissue imaging technologies: Imaging Mass Cytometry™ (IMC™) and the Maxpar® Direct™ Immune Profiling Assay™. The ADSCC, founded in 2019, is a specialist health care center that focuses on cell therapy and regenerative medicine in addition to cutting-edge stem cell research. The Cent
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under
Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm's current largest holder of common stock, under which Caligan has agreed to vote "FOR" all Fluidigm proposals related to the
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem in South San Francisco and appointed Gajus Worthington to its Board of Directors. The Company is now positioned to accelerate the translation of its proprietary cf-mRNA Liquid Biopsy Technology Platform to develop products and services for Precision Medicine clinical practice and biopharma R&D. "We
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the company’s Board of Directors. Dr. Stankovic is a seasoned leader with more than 30 years of research and development experience in academic, government, in vitro diagnostic and device industry settings. Dr. Stankovic is currently managing partner at Koliada Consulting, LLC, a firm focused on biotech, medical devices and in vitro diagnostics. Previously, she was Senior Vice President, World Wide Region
Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the third quarter ended September 30, 2021. "We saw a very active third quarter and made progress with our ambitious plan to commercially scale two new instrument systems," said Chris Linthwaite, President and CEO. "Core demand for our products was healthy, but we were unable to fulfill all orders for our products during the quarter, largely due to supply chain issues. Our b
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 8, 2021, to discuss third quarter 2021 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals int
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the second quarter ended June 30, 2021. "Second quarter results were driven by a rebound in our base business and early customer orders following the launch of our new fourth generation CyTOF® XT mass cytometry product," said Chris Linthwaite, President and CEO. "Our services busines
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13G - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D/A - FLUIDIGM CORP (0001162194) (Subject)
SC 13G - FLUIDIGM CORP (0001162194) (Subject)
SC 13G - FLUIDIGM CORP (0001162194) (Subject)
SC 13G/A - FLUIDIGM CORP (0001162194) (Subject)
SC 13G/A - FLUIDIGM CORP (0001162194) (Subject)
SC 13G/A - FLUIDIGM CORP (0001162194) (Subject)